Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
46
NRXP Quote, Financials, Valuation and Earnings
Last price:
$2.62
Seasonality move
:
51.98%
Day range:
$2.54 - $2.73
52-week range:
$1.47 - $6.01
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
191.27x
P/B ratio:
--
Volume:
620.1K
Avg. volume:
478.3K
1-year change:
23.18%
Market cap:
$76.1M
Revenue:
--
EPS (TTM):
-$2.35
Analysts' Opinion
-
Consensus RatingNRX Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $36.50, NRX Pharmaceuticals, Inc. has an estimated upside of 1246.86% from its current price of $2.71.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $25.00 representing 100% downside risk from its current price of $2.71.
Fair Value
-
According to the consensus of 4 analysts, NRX Pharmaceuticals, Inc. has 1246.86% upside to fair value with a price target of $36.50 per share.
NRXP vs. S&P 500
-
Over the past 5 trading days, NRX Pharmaceuticals, Inc. has overperformed the S&P 500 by 14.79% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
NRX Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
NRX Pharmaceuticals, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter NRX Pharmaceuticals, Inc. reported revenues of $242K.
Earnings Growth
-
NRX Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter NRX Pharmaceuticals, Inc. reported earnings per share of -$0.26.
Enterprise value:
79.4M
EV / Invested capital:
--
Price / LTM sales:
191.27x
EV / EBIT:
--
EV / Revenue:
327.97x
PEG ratio (5yr expected):
-0.12x
EV / Free cash flow:
-6.69x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$103K
Return On Assets:
-535.51%
Net Income Margin (TTM):
-15727.69%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-1701.65%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $242K | -- | $242K | |
| Gross Profit | -$5K | -$5K | $103K | -$2K | $104K | |
| Operating Income | -$33.1M | -$20.5M | -$15.2M | -$3M | -$4.1M | |
| EBITDA | -$33.1M | -$20.5M | -$15.2M | -$3M | -$4.1M | |
| Diluted EPS | -$5.11 | -$2.15 | -$2.35 | -$0.15 | -$0.26 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $45.2M | $24.8M | $13.1M | $4.1M | $11.9M | |
| Total Assets | $45.3M | $24.8M | $13.1M | $4.5M | $15M | |
| Current Liabilities | $36.8M | $8M | $19.3M | $20.3M | $40.6M | |
| Total Liabilities | $36.8M | $8M | $19.3M | $23.3M | $40.8M | |
| Total Equity | $8.5M | $16.8M | -$6.2M | -$18.8M | -$25.8M | |
| Total Debt | -- | -- | -- | $6M | $10.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$26.8M | -$12.4M | -$11.9M | -$2M | -$2.9M | |
| Cash From Investing | -$3K | $1K | -$2.6M | -- | -$2.6M | |
| Cash From Financing | $17.4M | $5.1M | $20M | $1.7M | $9.7M | |
| Free Cash Flow | -$26.8M | -$12.4M | -$11.9M | -$2M | -$2.9M | |
NRXP
Sector
Market Cap
$76.1M
$28.1M
Price % of 52-Week High
45.09%
50%
Dividend Yield
0%
0%
Shareholder Yield
-13.71%
-1.54%
1-Year Price Total Return
23.18%
-17.67%
Beta (5-Year)
1.621
0.503
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.49
200-day SMA
Buy
Level
$2.65
Bollinger Bands (100)
Sell
Level
2.33 - 3.11
Chaikin Money Flow
Sell
Level
-16.1M
20-day SMA
Buy
Level
$2.34
Relative Strength Index (RSI14)
Buy
Level
62.09
ADX Line
Buy
Level
18.16
Williams %R
Sell
Level
-2.5974
50-day SMA
Buy
Level
$2.53
MACD (12, 26)
Buy
Level
0.04
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
72.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-129.8992)
Sell
CA Score
(Annual)
Level (-33.5973)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (64.7636)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (0)
Revenue Forecast
Earnings per Share Forecast
Company Profile
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded by Jonathan C. Javitt on September 18, 2017 and is headquartered in Wilmington, DE.
Stock Forecast FAQ
In the current month, NRXP has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NRXP average analyst price target in the past 3 months is $36.50.
-
Where Will NRX Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that NRX Pharmaceuticals, Inc. share price will rise to $36.50 per share over the next 12 months.
-
What Do Analysts Say About NRX Pharmaceuticals, Inc.?
Analysts are divided on their view about NRX Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that NRX Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $25.00.
-
What Is NRX Pharmaceuticals, Inc.'s Price Target?
The price target for NRX Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $36.50 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NRXP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for NRX Pharmaceuticals, Inc. is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NRXP?
You can purchase shares of NRX Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase NRX Pharmaceuticals, Inc. shares.
-
What Is The NRX Pharmaceuticals, Inc. Share Price Today?
NRX Pharmaceuticals, Inc. was last trading at $2.62 per share. This represents the most recent stock quote for NRX Pharmaceuticals, Inc.. Yesterday, NRX Pharmaceuticals, Inc. closed at $2.71 per share.
-
How To Buy NRX Pharmaceuticals, Inc. Stock Online?
In order to purchase NRX Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get NRXP Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NRXP
Sector
P/E ratio
--
23.88x
PEG ratio
-0.12x
-0.01x
P/B ratio
--
1.82x
Price / LTM sales
191.27x
1.59x
Growth Metrics
NRXP
Sector
Revenue growth
--
4.73%
Earnings growth
-79.11%
11.11%
Revenue (5-year growth)
--
6.46%
Earnings forecast
-$0.06
-$0.18
Profitability
NRXP
Sector
Profitability FY 2024
-$5K
$3.6M
Return on invested capital
--
-31.77%
Return on assets
-535.51%
-28.18%
Return on equity
--
-37.47%
Earnings Date
Last Earnings Date
Nov
17
Next Earnings Date
Mar
17
Estimated Next Earnings Date
Feb
16
Balance Sheet
NRXP
Sector
Total cash
$7.2M
$26.3M
Short term investments
--
$26M
Total assets
$3.7M
$76.9M
Long term debt
$10.1M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
45
CTEV alert for Jan 2
Claritev Corp. [CTEV] is down 20.7% over the past day.
Sell
47
ASTS alert for Jan 2
AST Spacemobile, Inc. [ASTS] is up 14.94% over the past day.
Sell
45
BIDU alert for Jan 2
Baidu, Inc. [BIDU] is up 15.01% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
